Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    From $11.99/month after trial. Cancel anytime.

    Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management
    Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management
    Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management
    Ebook172 pages1 hour

    Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management

    By F. Foss, M. Ahearne and C.P. Fox

    ()

    Read preview

    About this ebook

    The peripheral T-cell lymphomas (PTCLs) are a heterogenous group of rare entities. Whilst cytogenetic and molecular identifiers are being identified, accurate diagnosis remains challenging, requiring careful, expert integration of the clinical and pathological findings. The treatment of PTCL is also challenging. Protocols for the different subtypes are only just beginning to emerge, hindered by the complexities of conducting trials in such uncommon and varied conditions. While first-line treatment with conventional chemotherapy is seldom curative, patients who achieve remission may be eligible for stem cell transplantation, offering the possibility of long-term disease control if not cure. Targeted biologics are also being developed as unique cytotoxic markers are identified. 'Fast Facts: Peripheral T-Cell Lymphomas' is a new title in the Fast Facts extensive hemato-oncology library, written by experts in this emerging field. This handbook will be useful to anyone involved in the care of patients with PTCL, including haematologists, oncologists, specialist nurses and primary care providers, raising awareness of these rare lymphomas and the current – and emerging – approaches to diagnosis and treatment.
    LanguageEnglish
    PublisherS. Karger
    Release dateJun 20, 2019
    ISBN9781912776191
    Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management

    Related authors

    Related to Fast Facts

    Related ebooks

    Medical For You

    View More
    View More

    Related podcast episodes

    Related articles

    • UNLIMITED

      Opinion: Testing Medical Students Is Big Business. I See It As Extortion

      Mar 20, 2020

      As medical students plod along in the physician-trainee pipeline, it's easy for us to feel helpless in the face of community-sanctioned extortion by the National Board of Medical Examiners.

      3 min read

    • UNLIMITED

      What Defines a Stem Cell?

      Dec 27, 2018

      For the past three years, researchers at the Hubrecht Institute in the Netherlands have been painstakingly cataloging and mapping all the proliferating cells found in mouse hearts, looking for cardiac stem cells. The elusive cells should theoreticall

      5 min read

    • UNLIMITED

      The Best Integrative Cancer Specialists

      Nov 21, 2021

      The Best Integrative Cancer Specialists
      5 min read

    • UNLIMITED

      Healing The Whole Person

      Jul 24, 2022

      The UK National Health Service reports that one in two people in the UK will develop cancer at some time in their lives. This is a stark and rather frightening statistic, not only because cancer is a leading cause of death but also because the usual

      7 min read

    • UNLIMITED

      Beating Cancer

      Feb 1, 2019

      Is cancer still a death sentence? No. Most cancers are preventable and also treatable. Cancer diagnosis and treatment have grown by leaps and bounds. We know the cause of at least 70 per cent of cancers now, around 60 per cent of cancers are now prev

      4 min read

    • UNLIMITED

      Keto Supplement May Improve Immunotherapy For Prostate Cancer

      Apr 30, 2024

      Adding a pre-ketone supplement, a component of a high-fat, low-carb ketogenic diet, to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer, researchers report. As reported in the journal Cancer Research,

      3 min read

    • UNLIMITED

      THE renaissance OF CELL THERAPIES

      Jul 28, 2019

      DR MARKUS DEPFENHART, PLASTIC AND AESTHETIC SURGEN In the late 1990s and early 2000s, there was huge hype around stem cells and their apparently almost unlimited potential, but unfortunately the expectations didn’t materialise. However, new scientifi

      2 min read

    • UNLIMITED

      Detecting Cancer At The Earliest Stages

      Jul 24, 2022

      Detecting Cancer At The Earliest Stages
      7 min read

    • UNLIMITED

      Coping with RECTAL CANCER

      Jun 8, 2022

      Coping with RECTAL CANCER
      2 min read

    • UNLIMITED

      Opinion: Precision Medicine Has A Blind Spot: Children With Cancer

      Dec 30, 2019

      We must do more to help patients and families across the arc of their cancer experiences, from coping with cancer diagnoses to breaking down barriers to care and living with…

      3 min read

    • UNLIMITED

      Piercing Cancer's Inner Sanctum

      Nov 24, 2023

      Piercing Cancer's Inner Sanctum
      15 min read

    • UNLIMITED

      Weight-loss Drug Could Fight Resistant Lung Cancer

      Aug 5, 2018

      New research could pave the way for using versions of an existing drug to keep lung cancer cells from becoming drug-resistant. Researchers have discovered that a key enzyme in lipid metabolism controls the response to a class of targeted drugs called

      2 min read

    • UNLIMITED

      Thrombotic Thrombocytopenic Purpura (TTP) – a Rare Presentation with COVID-19

      Sep 1, 2022

      1 Department of General Medicine, Aster MIMS Hospital, Kozhikode, Kerala, India 2 Department of Nephrology, Aster MIMS Hospital, Kozhikode, Kerala, India Dr. Jabir M P, Consultant, Department of General Medicine, Aster MIMS, Kozhikode-673016 Email: j

      5 min read

    • UNLIMITED

      A Game Changer For Cancer?

      Jul 30, 2020

      A Game Changer For Cancer?
      4 min read

    • UNLIMITED

      Drug In The Pipeline Helps Stem Cell Transplants Too

      Apr 29, 2018

      An investigational drug in clinical trials for rheumatoid arthritis also prevents a common, life-threatening side effect of stem cell transplants, new research shows. Studying mice, the researchers found the drug prevented what’s known as graft-versu

      3 min read

    • UNLIMITED

      Don’t Put All Your Eggs In One Basket

      May 23, 2021

      It baffles me how myopic we humans can be when trying to find solutions to some of our biggest challenges. Many thought nuclear power could be a one-stop replacement for fossil fuel, but it turned out to come with numerous problems, especially the ri

      3 min read

    Related categories

    Reviews for Fast Facts

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words

      Book preview

      Fast Facts - F. Foss

      Introduction

      The peripheral T-cell lymphomas (PTCL) are a heterogeneous group of rare entities, accounting for 10–15% of non-Hodgkin lymphomas. These lymphomas commonly arise in extranodal sites as well as in nodal tissue.

      The classification of the PTCLs is evolving but is traditionally based on clinical presentation, encompassing nodal, extranodal and leukemic types. The accurate diagnosis of PTCL subtypes is challenging and requires careful integration of the clinical picture, morphology, immunohistochemistry, flow cytometry, cytogenetics and molecular biology.

      By contrast with the B-cell lymphomas, we are only just beginning to develop individualized treatment algorithms based on PTCL subtype. First-line treatment with conventional chemotherapy is often not curative but patients in remission may proceed to consolidative stem cell transplantation, which may offer an increased chance of cure, or at least long-term disease control. Clinical and biological heterogeneity across the PTCL subtypes presents challenges in the design and conduct of potentially practice-changing comparative clinical trials, and, overall, the prognosis remains guarded for most patients.

      Whilst the diagnosis and treatment of PTCL require specialist expertise, this new Fast Facts title provides an informative overview that will be useful to anyone involved in the care of patients with PTCL, including hematologists, oncologists, specialist nurses and primary care providers, as well as medical students. This resource raises awareness of these rare lymphomas and describes the current – and emerging – approaches to diagnosis and treatment.

      The immune system combats foreign pathogens through innate and acquired (or adaptive) immunity (Figure 1.1).

      • Innate immunity offers a rapid but non-specific defense. It comprises the physical epithelial barrier, complement activation, some T cells and natural killer (NK) cells, and phagocytic cells (neutrophils and macrophages) which engulf and remove pathogens.

      • In the adaptive immune system, T and B cells recognize and respond to specific antigens, producing a tailored response to invading pathogens. Persistence of these ‘experienced’ T and B cells results in long-term immune memory.

      Figure 1.1 Pathogens are recognized by a variety of immune cells. The body’s initial non-specific innate immunity is triggered in the first critical hours of exposure to a new pathogen. The adaptive immunity develops over several days in response to specific antigens.

      T cells

      T cells develop from progenitors within the thymus gland. Mature T cells can be broadly classified into two types:

      • T-helper cells, which are primarily involved in coordinating the immune response to an invading organism

      • cytotoxic T cells, which kill cells infected with microorganisms.

      T-cell receptors (TCRs) are analogous to the immunoglobulin molecules in B cells. Early T cells express TCRs in germline configuration. Recombination of TCR genes during maturation of T cells produces a unique TCR configuration – a critical feature of protective immunity that enables mature T cells to recognize and respond to a broad range of foreign material.

      TCRs comprise two different protein chains (i.e. they are heterodimers), most often an alpha and beta subunit (αβ T cells). These αβ T cells recognize and bind foreign peptides presented by major histocompatibility complex (MHC) molecules on the cell surface of antigen-presenting cells. This MHC–antigen complex binds to αβ TCRs, while other co-stimulatory molecules (e.g. CD28) are activated, leading to αβ T-cell activation, proliferation, differentiation and apoptosis and cytokine release.

      About 5% of T cells express a gamma and delta TCR (γδ T cells). These cells have similarities with NK cells, with roles in both innate and adaptive immune responses.¹ They are typically found at sites of antigen contact, such as the skin, spleen, liver, intestine and bone marrow. As a first line of defense after antigenic stimulus, γδ T cells release cytotoxic factors (perforins, granzyme B and TIA-1). The γδ TCR is expressed by several extranodal subtypes of PTCL (see Chapter 2).

      CD4 and CD8. Lymphoid progenitor cells in the thymus undergo stepwise maturation (Figure 1.2). The developing cells, called thymocytes, do not initially express CD4 or CD8 (described as double negative); expression of CD4 and CD8 is driven by positive signals received during development, resulting in double-positive thymocytes. Double-positive cells also encounter self-antigens and those that exhibit self-reactivity undergo negative selection. Finally, either CD4 or CD8 is downregulated, resulting in single-positive cells. The naive CD4+ and CD8+ T cells enter the peripheral circulation from the thymus.

      Figure 1.2 T-cell development. T-cell precursors in the thymus (thymocytes) develop into mature single-positive CD4+ or CD8+ cells. DN, double negative; DP, double positive; NK, natural killer; SP, single positive.

      CD8+ T cells recognize antigens presented by the MHC class I molecules found on nucleated cells. Once activated, the CD8+ T cells proliferate to produce cytotoxic T lymphocytes – a population of effector T cells which release the enzymes and toxins that induce apoptosis.

      CD4+ T cells recognize antigens presented by MHC class II molecules, which are only present on specialized antigen-presenting cells. Most of these cells are ‘helper’ subsets, which release cytokines, sending positive signals to other immune cells, predominantly B cells (Figure 1.3). A unique subset of CD4+ T cells, called T regulatory cells, restrain the immune response via various cytokine and signaling mechanisms, preventing aberrant or exaggerated immune activation.² Follicular helper T cells provide essential support for B-cell immune responses.³

      Our understanding of T-cell subsets has advanced significantly over recent years. The external signals (cytokines) that trigger polarized T-cell differentiation are being elucidated, as are the molecular mechanisms that alter T-cell behavior to produce specific effector functions. Furthermore, gene expression profiling is being used to define the molecular signatures of T-cell subsets. These insights are refining our understanding of PTCL subtypes and have allowed the cell of origin to be identified for some (see Chapter 2).⁴

      Figure 1.3 Differentiation of naive CD4 cells into helper T-cell subsets. CD4, cluster of differentiation; IFN, interferon; IL, interleukin; Tfh, follicular helper T cell; TGF, transforming growth factor; Th, helper T cell; TN, naive T cell; TNF, tumor necrosis factor; Treg, regulatory T cell.

      Natural killer cells

      NK cells are a type of lymphocyte derived from the same common lymphoid progenitor as B and T lymphocytes but develop primarily in the bone marrow. NK cells are typically considered part of the innate immune system because they rapidly produce inflammatory cytokines and directly kill infected cells without prior priming or activation. However, recent evidence suggests that NK cells are also important in adaptive immunity.⁵

      Key points – T-cell biology

      • T cells develop in the thymus and are part of the innate and adaptive immune system. They recognize and respond to specific antigens, producing a tailored response to invading pathogens.

      • Mature T cells express a surface T-cell receptor (TCR) that recognizes fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules.

      • Thymocytes do not express CD4 or CD8 initially (double-negative) but become double-positive during development, after which one molecule is downregulated. CD8 + T cells (cytotoxic T lymphocytes) recognize antigens presented by the MHC class I molecules found on nucleated cells. CD4 + T cells, of which there are several subtypes, recognize antigens presented by MHC class II molecules, which are only present on specialized antigen-presenting cells.

      • Natural killer (NK) cells derive from the same common lymphoid progenitor as T cells but develop primarily in the bone marrow. They produce inflammatory cytokines and

      Enjoying the preview?
      Page 1 of 1